FLIXONASE

This brand name is authorized in Austria, Brazil, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Lithuania, Malta, Mexico, Nigeria, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, South Africa

Active ingredients

The drug FLIXONASE contains one active pharmaceutical ingredient (API):

1 Fluticasone
UNII O2GMZ0LF5W - FLUTICASONE PROPIONATE

Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically.

Read about Fluticasone

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
FLIXONASE Nasal drops Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FLIXONASE Nasal spray Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R01AD08 Fluticasone R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 510603001172315, 510603002179313
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 29604-1-01-11
Country: EE Ravimiamet Identifier(s): 1007233, 1173620, 1643228, 1762950
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 60483, 62771, R-2948IP
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 018285, 021100, 431809
Country: FR Base de données publique des médicaments Identifier(s): 61748649
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 138764, 142336, 181549, 196125, 28109, 381341, 43807
Country: HK Department of Health Drug Office Identifier(s): 47400
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1073034, 1084743
Country: MT Medicines Authority Identifier(s): AA460/00801, MA192/04101, PI1438/03901A, PI908/02102A
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 441M95
Country: NG Registered Drug Product Database Identifier(s): 04-2629
Country: NL Z-Index G-Standaard Identifier(s): 14236664
Country: NL Z-Index G-Standaard, PRK Identifier(s): 67202, 72346
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 5254
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100024517, 100193504
Country: SG Health Sciences Authority Identifier(s): 07090P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 8573021
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699522543014
Country: ZA Health Products Regulatory Authority Identifier(s): 33/21.5.1/0329, X/21.5.1/359

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.